IRCT201111291414N29
Completed
Early Phase 1
Investigation on autologous mesenchymal stem cell transplantation in diabetic retinopathy
The EMRI Endocrinology and Metabolism Research Institute ? Tehran University of Medical Sciences0 sites20 target enrollmentTBD
Overview
- Phase
- Early Phase 1
- Intervention
- Not specified
- Conditions
- diabetic retinopathy (dibetes type one).
- Sponsor
- The EMRI Endocrinology and Metabolism Research Institute ? Tehran University of Medical Sciences
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •People with diabetes type one with at least 10 years duration ;Age 18\-40 years;Signing informed consent;Patients with diabetic retinopathy diagnosed by an ophthalmologist ;HbA1c \= 7\.5% (blood glucose is controlled at least for one month);All eligible patients for celltherapy (according to standard protocol ); BP\=130/80 ;Cardiac Consultation form that is filled by a cardiologist (Cardiac echocardiography and ECG)
- •Exclusion criteria: Acute vascular inflammation ; Acute thrombosis (three months); Pulmonary hypertension;Liver disease; Hematological malignancy and bone marrow cancer;Infectious diseases;Mental illness; Generalized edema ; Malignancy; pregnancy ; Sensitivity to the fluorescein
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Effect of mesenchymal stem cells transplantation to improve of diabetic neuropathyDiabetic neurophaty.Diabetic polyneuropathy (E10-E14 with common fourth character .4+)G63.2*IRCT201103171414N23???Endocrinology & Metabolism Research Institute Tehran University Of Medical Sciences20
Completed
Early Phase 1
Investigation on autologous mesenchymal stem cell transplantation in diabetic nephrophaty (type one)Diabetes Nephropathy (type 1).Glomerular disorders in diabetes mellitusIRCT201111291414N28Endocrinology and Metabolism Research Institute (EMRI)20
Active, not recruiting
Phase 1
SMART-MSMultiple sclerosisMedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]CTIS2023-510228-63-00Helse Bergen HF18
Not yet recruiting
Phase 2
SMART-MS2023-510228-63-00Helse Bergen HF18
Completed
Not Applicable
Mesenchymal stem cell transplantation in the treatment of type 1 diabetic patientsType 1 diabetes.Insulin-dependent diabetes mellitusIRCT138810271414N8Endocrinology & Metabolism Research Center20